psilocybin therapies

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression Partners Beckley Psytech and atai Life Sciences (NASDAQ:ATAI) have jointly announced positive initial results from a Phase 2a study of Beckley’s novel formulation of 5-MeO-DMT in Treatment Resistant Depression...

Indiana Gov. Eric J. Holcomb (R) acted swiftly on the passing of a health bill, which includes provisions to fund clinical research trials into psilocybin. Sent by the state legislators to his desk on March 12, the governor officially signed the proposal into law the following day, March 13. The...

Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:CYBN) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated psilocybin analog targeting the adjunctive treatment of Major Depressive Disorder (MDD.)  The...

Research and regulatory collaboration between Canadian biotechs Red Light Holland (OTCQB:TRUFF) and PharmAla (OTC:MDXXF) is bearing fruit. The partners are moving forward with a new project to bring Active Pharmaceutical Ingredient (API) extraction from Red Light’s psilocybin truffles to a...

Compass Pathways (NASDAQ:CMPS), one of the key players in the psychedelics biotech space, reported its financial results for the fourth quarter of 2023. Numbers: Cash and cash equivalents were $220.2 million by December 31, 2023, up over 50% as compared to the amount held by December 31, 2022 ($...

Welcome to the second episode of the Benzinga Psychedelics Podcast. This time, we are joined by psychedelics advocate and entrepreneur Justin Townsend, partner and CEO of psilocybin retreat center MycoMeditations.  In this conversation, you'll find a thorough guide for the main divides within the...

Certain fungi species that spontaneously produce psilocybin, a powerful substance that activates the serotonin 5-HT2A receptor in the brain and produces psychedelic effects like heightened perception, imagery, complex hallucinations and time distortions, are often called psychedelic or magic...

New Study Reveals Suggestibility’s Role In Antidepressant Effects Of Psilocybin Therapy A new study led by Balázs Szigeti and with involvement of researchers Brandon Weiss, Fernando E Rosas, David Erritzoe, David Nutt and Robin Carhart-Harris found evidence of suggestibility predicting an...

Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  Research Disorders due to substance use: Hallucinogens and MDMA-related...

Dr. Sunil Aggarwal’s long-standing battle for the federal rescheduling of psilocybin for end-of-life cancer patients just hit another obstacle. What Happened: According to Marijuana Moment, the Washington-based doctor began seeking permission to provide the therapy from state and federal...

Following a potential drug-dealing lead, a joint drug task force with federal, state and local law enforcement authorities raided a property in Burlington, Connecticut and found large bags of psilocybin mushrooms worth around $8.5 million. Officials raided the home on...

Recently published findings from a Canada-based survey conducted by U.S. and Canadian universities and completed by 1,249 participants reflect that using psilocybin can help ease psychological distress from adverse childhood experiences.  The study participants over 16 filled out a ...

Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program (SAP.)  Since Jan. 2022 physicians have been allowed to request...

Silo Wellness (OTCQB: SILFF) has confirmed its intention to acquire all issued and outstanding securities of NUGL Inc./Kaya Group (OTC Pink: NUGL) in an arms-length transaction valued at $31.9 (CA$43.3) million. The news comes shortly after Cybin's (NYSE: CYBN) proposed...

Findings from a new study conducted by novel therapeutics cancer firm Sunstone Therapies and the University of Vermont’s Conversation Lab show the feasibility of trained human coders to identify observable markers of therapeutic connection during psilocybin administration within...